Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

PHASE1CompletedINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

December 30, 2018

Study Completion Date

March 30, 2019

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

iNKT cells

The patients received different doses of in vitro-expanded autologous iNKT cells through intravenous infusion. The dosage was escalated from 3x10\^7 cells/m2 to 6x10\^7 cells/m2 to 9x10\^7 cells/m2. The maximum tolerated dose (MTD) was defined as the last dose level, and the dosage would be up to 1x10\^10 cells/m2 if no MTD was observed after a 3+3 design.

DRUG

IL-2

IL-2 will be given at a dose of 25,000 IU/kg/day for 5-14 days.

DRUG

Tegafur

Tegafur will be given at a dose of 40\~60 mg bis in die (BID) 2 weeks.

Trial Locations (1)

100069

Beijing Youan Hospital,Capital Medical University, Beijing

All Listed Sponsors
lead

Beijing YouAn Hospital

OTHER

NCT03175679 - Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC | Biotech Hunter | Biotech Hunter